Department of Pediatric Neurology, Xi'an Jiaotong University Affiliated Children's Hospital, Xi'an 710003, China.
Department of Pediatric Neurology, Xi'an Jiaotong University Affiliated Children's Hospital, Xi'an 710003, China.
Seizure. 2023 Aug;110:238-243. doi: 10.1016/j.seizure.2023.07.004. Epub 2023 Jul 7.
This study was conducted to compare the efficacy, tolerability and safety of the modified Atkins diet (MAD) and the classic ketogenic diet (KD) in Chinese children with infantile epileptic spasms syndrome.
We retrospectively recruited and analyzed 56 children with infantile epileptic spasms syndrome started on the MAD (n = 21) and classic KD (n = 35) at our institution from June 2016 to July 2022.
The MAD group had exhibited comparable rates of spasm reduction (>50%) as the classic KD group at the time point of 3 months (66.7% for MAD, 75% for KD; p = 0.510), 6 months (75% for MAD, 82.6% for KD; p = 0.694), and 12 months (84.6% for MAD, 90.9% for KD; p = 1.000). The probability of patients remaining on the MAD was higher (p = 0.048) than those consuming the classic KD. By analyzing discontinuation reasons, we found that the MAD patients had a lower rate of poor compliance than the classic KD patients (p = 0.014). Response to the diet at 1 month and fewer anti-seizure medicines (ASMs) had tried before KD initiation were possible factors in regard to likelihood of spasm-free response to the diet therapy at 3 months (p = 0.001 and p = 0.014, respectively).
The efficacy of spasm control was similar in the MAD, with better tolerability and higher compliance compared to the classic KD. Therefore, MAD could be the primary treatment for children in China with- infantile epileptic spasms syndrome. Additionally, an earlier beginning of the diet treatment may have significant advantages.
本研究旨在比较改良阿特金斯饮食(MAD)和经典生酮饮食(KD)在我国婴儿痉挛症患儿中的疗效、耐受性和安全性。
我们回顾性招募并分析了 2016 年 6 月至 2022 年 7 月在我院开始接受 MAD(n=21)和经典 KD(n=35)治疗的 56 例婴儿痉挛症患儿。
MAD 组在 3 个月(MAD 组为 66.7%,KD 组为 75%;p=0.510)、6 个月(MAD 组为 75%,KD 组为 82.6%;p=0.694)和 12 个月(MAD 组为 84.6%,KD 组为 90.9%;p=1.000)时痉挛减少率(>50%)与 KD 组相当。继续使用 MAD 的患者比例更高(p=0.048)。通过分析停药原因,我们发现 MAD 患者的依从性较 KD 患者差(p=0.014)。饮食治疗 1 个月时的反应和开始 KD 前尝试的抗癫痫药物(ASM)种类较少是 3 个月时无痉挛反应的饮食治疗可能性因素(p=0.001 和 p=0.014)。
MAD 控制痉挛的疗效与 KD 相似,但耐受性和依从性优于 KD。因此,MAD 可能成为我国婴儿痉挛症患儿的主要治疗方法。此外,更早开始饮食治疗可能具有显著优势。